Skip to content

Cholic acid

Bile Acid — ALIMENTARY TRACT AND METABOLISM

Also known as: cholalic acid, cholalin, cholbam, colalin, kolbam, orphacol

OfpEMA approvedFDA approvedPMDA approvedOrphan designationATC A05AA03

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Cholic acid is an ofp drug in the Bile Acid class catalogued in DrugCentral. It was first approved by the EMA in 2013. DrugCentral lists 2 molecular targets, including GPBAR1 and NR1H4. Recorded indications include 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency, Calculus in biliary tract, Cholestanol storage disease and Constipation.

  • Approval status: ofp (first approved 2013 by the EMA).
  • Drug class: Bile Acid.
  • Molecular targets: GPBAR1 and NR1H4 (2 listed in DrugCentral).
  • Indications: 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency, Calculus in biliary tract, Cholestanol storage disease, Constipation and Delta-4-3-oxosteroid-5-beta-reductase deficiency and others.
  • ATC code: A05AA03 (Bile acids and derivatives).
  • Molecular formula: C24H40O5; molecular weight 408.58 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (8)

  • 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency
  • Calculus in biliary tract
  • Cholestanol storage disease
  • Constipation
  • Delta-4-3-oxosteroid-5-beta-reductase deficiency
  • Disorder of biliary tract
  • Inborn error of bile acid metabolism
  • Incomplete passage of stool

Contraindications (12)

  • Appendicitis
  • Diarrhea
  • Disease of liver
  • Gallstone Complications
  • Gastrointestinal obstruction
  • Hypercholesterolemia
  • Incontinence of feces
  • Liver function tests abnormal
  • Obstruction of bile duct
  • Pregnancy, function
  • Primary biliary cirrhosis
  • Sclerosing cholangitis

Mechanism & targets

Established pharmacologic classBile Acid

Molecular targets (2)

TargetGeneActionActivity
G-protein coupled bile acid receptor 1GPBAR1agonistEC50 5.00
Bile acid receptorNR1H4unknownEC50 4.35

Regulatory approvals (3)

DateAgencyMarketed asApplicantOrphan
2023-03-27PMDA—ReqMed Company, LtdYes
2015-03-17FDA—RTRXYes
2013-09-12EMA—Laboratoires CTRSYes

ATC classification

ATC codeTherapeutic hierarchy
A05AA03ALIMENTARY TRACT AND METABOLISM › BILE AND LIVER THERAPY › BILE THERAPY › Bile acids and derivatives

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label: AKR1D1, HSD3B7
  • FDA label: AKR1D1, AMACR, CYP27A1, CYP7A1, DHCR7

Chemical structure

Molecular formulaC24H40O5
Molecular weight408.58 g/mol
CAS number81-25-4
InChIKeyBHQCQFFYRZLCQQ-OELDTZBJSA-N
PubChem CID221493
C[C@H](CCC(O)=O)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cholic acid used for?

DrugCentral lists the following indications for Cholic acid: 3-Beta-hydroxy-delta-5-C27-steroid dehydrogenase deficiency, Calculus in biliary tract, Cholestanol storage disease, Constipation, Delta-4-3-oxosteroid-5-beta-reductase deficiency, Disorder of biliary tract, Inborn error of bile acid metabolism and Incomplete passage of stool.

How does Cholic acid work?

Its molecular targets in DrugCentral include GPBAR1 (agonist) and NR1H4.

When was Cholic acid first approved?

Cholic acid was first approved by the EMA in 2013.

What drug class does Cholic acid belong to?

Cholic acid is in the Bile Acid class.

What is the chemical formula of Cholic acid?

Cholic acid has the molecular formula C24H40O5 and a molecular weight of 408.58 g/mol.

Browse: all drugs starting with C · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2013-09-12
AgencyEMA
Targets2
Indications8
FormulaC24H40O5
DrugCentral ID3096
Interactive profile